CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
Caffeine +1 moredrug
Likely dose
Caffeine 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00879775
NCT00879775Phase 2Completed

Efficacy of Caffeine as an Adjuvant to Opioid Therapy in Cancer Pain: a Randomized, Double-blind, Placebo-controlled Trial

Korea Research Foundation·interventional·Posted Apr 10, 2009·Updated Mar 29, 2011

In Brief

A Phase 2 clinical trial evaluating Caffeine and Normal saline for Cancer and Pain. Completed, enrolled 41 participants across 2 sites.

Detailed Summary

Pain is a most common symptom and it has a high impact on quality of life in cancer patients. Many cancer patients have received opioid therapy, but also many of them have suffered from side effects of opioids. Drowsiness and confusion are common side effects of opioids. Caffeine is a well known psychostimulant,and it is widely used as an analgesics. Thus, the investigators aimed to prove the efficacy of intravenous caffeine administration as an adjuvant analgesics to opioids. At the same time, the investigators tried to find that the side effects of opioids could be ameliorated by caffeine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Pain
CountriesSouth Korea

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 10, 2009
Enrollment StartApr 1, 2009
Primary CompletionJul 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.2 years ago

Interventions

Caffeinedrug

Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.

Normal salinedrug

Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days